Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S.

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug ...

In a decision signed Monday, North Carolina federal judge Kenneth Bell granted Merck’s motion to dismiss the claims of ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of ...